Management of Apixaban for ERCP
For ERCP with stenting only (low-risk procedure), continue apixaban and simply omit the morning dose on the day of the procedure; for ERCP with sphincterotomy (high-risk procedure), discontinue apixaban at least 48 hours before the procedure.
Risk Stratification of ERCP
The critical first step is determining whether your ERCP involves sphincterotomy or other high-risk interventions:
- Low-risk ERCP: Biliary or pancreatic stenting without sphincterotomy 1
- High-risk ERCP: ERCP with sphincterotomy ± balloon sphincteroplasty 2, 1
This distinction fundamentally changes anticoagulation management and cannot be overlooked.
Management Algorithm
For Low-Risk ERCP (Stenting Only)
Continue apixaban through the procedure with minimal interruption 1:
- Simply omit the morning dose on the day of the procedure
- Resume regular dosing after the procedure once hemostasis is confirmed
- No bridging anticoagulation required
The BSG/ESGE guidelines explicitly recommend continuing DOACs for low-risk procedures with only the morning dose omitted 1.
For High-Risk ERCP (With Sphincterotomy)
Discontinue apixaban at least 48 hours before the procedure 1:
- Take the last dose of apixaban ≥48 hours before the scheduled procedure
- For patients with CrCl 30-50 mL/min: Extend to 72 hours before the procedure 1
- No heparin bridging is required for most patients 2
- The FDA label confirms discontinuation at least 48 hours prior for procedures with moderate or high bleeding risk 3
Important caveat: If the patient has rapidly deteriorating renal function, consult hematology before proceeding 1.
Thrombotic Risk Considerations
The management differs based on thrombotic risk stratification 2:
Very High Thrombotic Risk
- ACS or PCI <6 weeks: Defer the procedure if possible 2
High Thrombotic Risk
- ACS or PCI 6 weeks to 6 months ago: Defer until >6 months if possible
- If procedure cannot be deferred: Withhold apixaban 2 days before, resume after adequate hemostasis, no heparin bridging 2
Moderate to Low Thrombotic Risk
- ACS or PCI >6 months ago, stable coronary disease, AF without recent events
- Withhold apixaban 2 days before, resume after adequate hemostasis, no heparin bridging 2
Post-Procedure Resumption
Resume apixaban within 24-48 hours after the procedure depending on bleeding and thrombotic risks 1:
- If adequate hemostasis achieved: Resume as soon as safely possible
- Balance the competing risks of thrombosis versus post-procedure bleeding
- The FDA label states to restart "as soon as adequate hemostasis has been established" 3
Evidence Quality and Nuances
The BSG/ESGE 2016 guidelines 1 and APAGE/APSDE 2018 guidelines 2 provide concordant recommendations despite being from different geographic regions. However, the evidence quality for DOAC management is rated as "very low quality" for the 48-hour discontinuation recommendation, though it remains a "strong recommendation" based on pharmacokinetic principles 1.
Research data supports this approach: A prospective study found that apixaban discontinuation for at least 48 hours resulted in 94% of patients achieving concentrations ≤30 ng/mL, with clinically insignificant anticoagulation prior to surgery 4. The apixaban half-life is approximately 12 hours 5, making the 48-hour window (approximately 4 half-lives) pharmacologically sound.
Common Pitfalls to Avoid
Don't bridge with heparin: Unlike warfarin management, DOACs including apixaban do not require bridging anticoagulation 2, 1
Don't use INR or aPTT to monitor: These tests are unreliable for assessing apixaban effect 3
Check renal function: Patients with CrCl 30-50 mL/min require extended discontinuation to 72 hours 1
Verify the procedure type: Confirm whether sphincterotomy is planned, as this changes management from continuation to discontinuation
Don't assume all elderly patients need dose reduction: Only patients with ≥2 of the following criteria should receive 2.5 mg twice daily: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL 3